[Studies on cephradine for intravenous injection (author's transl)]

Area of Science:

• Pharmacokinetics
• Infectious Diseases
• Nephrology

Background:

• Cephradine (CED) is an antibiotic used to treat bacterial infections.
• Understanding its pharmacokinetic profile, particularly in relation to renal function and drug interactions, is crucial for optimizing therapeutic outcomes.

Purpose of the Study:

• To investigate the effect of probenecid on the serum half-life of cephradine in patients with normal renal function.
• To evaluate the pharmacokinetic behavior of cephradine in patients with severely impaired renal function.
• To assess the clinical efficacy and safety of cephradine in treating various infections.

Main Methods:

• Serum samples were analyzed to determine cephradine half-life in patients with normal renal function, with and without probenecid.
• Intravenous cephradine administration was given to patients with severely impaired renal function, and serum concentrations were measured.
• Clinical data from 17 patients treated with cephradine for lung, urinary tract, and bile duct infections were reviewed.

Main Results:

• The half-life of cephradine in patients with normal renal function was 30 minutes, increasing to 83 minutes when co-administered with probenecid.
• In patients with severely impaired renal function, mean serum cephradine concentration was 33 mcg/ml at 24 hours post-1g IV injection.
• Clinical efficacy was rated as excellent in 5 cases, good in 6, and undetermined in 1, with no significant adverse effects reported.

Conclusions:

• Probenecid significantly prolongs the serum half-life of cephradine in individuals with normal renal function, suggesting a potential drug interaction.
• Cephradine exhibits prolonged serum concentrations in patients with severe renal impairment.
• Cephradine appears to be an effective and well-tolerated antibiotic for treating common bacterial infections.